WALTHAM, Mass., Nov. 30, 2011 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD - News), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today the availability of the peer-reviewed publication of the first clinical study on the role of galectin-3 in heart failure development. Results of the pilot study, which consisted of a sub-study of patients from the Pravastatin or Atorvastin Evaluation and Infection Therapy -- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, indicate that serum levels of galectin-3 are associated with increased risk of developing heart failure after suffering an acute coronary event, such as a heart attack. The study was conducted by the Boston-based TIMI Study Group at Brigham & Women’s Hospital and Harvard Medical School. The results from the study were published in the November 22, 2011 online issue of the journal Clinical Chemistry, titled, “Galectin-3 and the Development of Heart Failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22,” Grandin E, Jarolim P, Murphy S. DOI 10.1373/clinchem.2011.174359.
